Godavari Biorefineries Limited (GODAVARIB)

Fast Moving Consumer Goods · Diversified FMCG · NSE · Updated 13 August 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹261.6 ↓ 4.63% (1Y)

🎯 Key Takeaways

Godavari Biorefineries Limited is in a strategic growth and transformation phase, shifting from a traditional FMCG focus to a bio-refinery model centered on ethanol, bio-based chemicals, and pharmaceutical intermediates. The company is investing in capacity expansion and innovation, including a newly commissioned 200 KLPD grain-based distillery and clinical trials for an anti-cancer molecule, but near-term profitability remains constrained by capital intensity and operational ramp-up costs.
Revenue grew 39.4% QoQ to ₹447 in Q3FY25.
⚠️ 1) Profitability remains under pressure despite margin expansion, with net losses continuing due to high capital and R&D expenditures. 2) The success

Market Cap

₹1,528

P/E Ratio

67.7

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About GODAVARIB 📊 Interactive Charts

📖 The Story

Godavari Biorefineries Limited is in a strategic growth and transformation phase, shifting from a traditional FMCG focus to a bio-refinery model centered on ethanol, bio-based chemicals, and pharmaceutical intermediates. The company is investing in capacity expansion and innovation, including a newly commissioned 200 KLPD grain-based distillery and clinical trials for an anti-cancer molecule, but near-term profitability remains constrained by capital intensity and operational ramp-up costs.

📰 What's Happening

In Q1 FY27, the company reported total income of ₹559.9 crores, up from ₹534.0 crores YoY, driven by expansion in ethanol production and bio-based chemical initiatives. Management highlighted the commissioning of a new distillery boosting ethanol capacity to 800 KLPD and the submission of a CDSCO application for clinical trials of an anti-cancer molecule. The board approved the Q1 results and scheduled the 71st AGM for September 28, 2026, where management is expected to provide further updates on the clinical trial timeline and capital allocation for R&D and capacity scaling.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q2FY25	Q3FY25
Revenue	321	447
Operating Profit	-32	40
OPM %	-10.2%	8.1%
Net Profit	-75	6
EPS	₹-17.88	₹1.31

Revenue growth has shown sequential and YoY improvement, rising to ₹559.9 crores in Q1 FY27 from ₹534.0 crores in Q1 FY26, reflecting successful execution of expansion projects. However, profitability remains under pressure, with net loss widening to ₹19.3 crores from ₹16.0 crores YoY, despite a significant EBITDA margin expansion to 53% from 8.9%. This margin improvement stems from operational efficiencies and higher-margin product mix, but sustained losses indicate ongoing investment in strategic initiatives rather than cost control.

🔮 Management Outlook & What's Next

Management has indicated that clinical trials for the anti-cancer molecule will commence in Q3 FY27, subject to regulatory approvals, and emphasized continued focus on scaling bio-refinery operations. The company is advancing its vertical integration in ethanol and bio-based chemicals, with plans to leverage new capacity for commercial output. No formal financial guidance was provided, but management reiterated confidence in long-term value creation through innovation and strategic partnerships in the green chemicals space.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Diversified FMCG

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Hindustan Unilever Limited	5.34 L Cr	36.8	27.4%	29.4%	0.00
ITC Limited	3.88 L Cr	11.1	38.9%	50.0%	0.00
Hindustan Foods Limited	6,215	58.9	—	—	—
Godavari Biorefineries Limited	1,528	67.7	—	—	—
Rana Sugars Limited	200	5.6	—	—	—

🔗 Peer Stock Analyses

HINDUNILVR ITC HNDFDS RANASUG

⚠️ Risk Factors

1) Profitability remains under pressure despite margin expansion, with net losses continuing due to high capital and R&D expenditures. 2) The success of the anti-cancer molecule's clinical trials is uncertain and subject to regulatory approval, introducing execution and timeline risks. 3) Integration of new bio-refinery capacity and commercialization of bio-based chemicals may face supply chain or market adoption challenges. 4) The company's shift from FMCG to bio-refineries requires sustained investment, which may delay breakeven and increase financial volatility.

📋 Recent Filings

🧠 Analyst's Read

Godavari Biorefineries is executing a clear strategic pivot toward bio-based chemicals and ethanol, supported by tangible capacity additions and innovation milestones. Investors should monitor the progress of clinical trials, commercialization of new products, and the pace of margin improvement as key near-term catalysts. The company's long-term potential hinges on successful execution of its bio-refinery vision, but near-term financial performance will likely remain volatile.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on GODAVARIB

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-13.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GODAVARIB files new disclosures

Track GODAVARIB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GODAVARIB — Free

Free account · 2 AI queries/day